Precision medicine: from pharmacogenomics to pharmacoproteomics.
作者： Allison B. Chambliss , Daniel W. Chan
DOI: 10.1186/S12014-016-9127-8
关键词:
摘要: Disease progression and drug response may vary significantly from patient to patient. Fortunately, the rapid development of high-throughput ‘omics’ technologies has allowed for identification potential biomarkers that aid in understanding heterogeneities disease treatment outcomes. However, mechanistic gaps remain when genome or proteome are investigated independently treatment. In this article, we discuss current status pharmacogenomics precision medicine highlight needs concordant analysis at metabolome levels via more recently-evolved fields pharmacoproteomics, toxicoproteomics, pharmacometabolomics. Integrated investigations will be critical piecing together targetable mechanisms action both monitoring therapy order fully apply clinic.
biomedcentral.com
elsevier.com
springer.com
core.ac.uk
paperity.org参考文章(79)
Hiltrud Brauch, Matthias Schwab, Prediction of tamoxifen outcome by genetic variation of CYP2D6 in post-menopausal women with early breast cancer. British Journal of Clinical Pharmacology. ,vol. 77, pp. 695- 703 ,(2014) , 10.1111/BCP.12229
Yuan Ji, Daniel J. Schaid, Zeruesenay Desta, Michiaki Kubo, Anthony J. Batzler, Karen Snyder, Taisei Mushiroda, Naoyuki Kamatani, Evan Ogburn, Daniel Hall-Flavin, David Flockhart, Yusuke Nakamura, David A. Mrazek, Richard M. Weinshilboum, Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations British Journal of Clinical Pharmacology. ,vol. 78, pp. 373- 383 ,(2014) , 10.1111/BCP.12348
SLCO1B1 variants and statin-induced myopathy--a genomewide study The New England Journal of Medicine. ,vol. 359, pp. 789- 799 ,(2008) , 10.1056/NEJMOA0801936
Mary V. Relling, William E. Evans, Pharmacogenomics in the clinic Nature. ,vol. 526, pp. 343- 350 ,(2015) , 10.1038/NATURE15817
Kenneth D. Levy, Victoria M. Pratt, Todd C. Skaar, Gail H. Vance, David A. Flockhart, FDA's draft guidance on laboratory-developed tests increases clinical and economic risk to adoption of pharmacogenetic testing. The Journal of Clinical Pharmacology. ,vol. 55, pp. 725- 727 ,(2015) , 10.1002/JCPH.492
R Kaddurah-Daouk, R Weinshilboum, , Metabolomic Signatures for Drug Response Phenotypes: Pharmacometabolomics Enables Precision Medicine. Clinical Pharmacology & Therapeutics. ,vol. 98, pp. 71- 75 ,(2015) , 10.1002/CPT.134
Federico Innocenti, Richard L. Schilsky, Jacqueline Ramírez, Linda Janisch, Samir Undevia, Larry K. House, Soma Das, Kehua Wu, Michelle Turcich, Robert Marsh, Theodore Karrison, Michael L. Maitland, Ravi Salgia, Mark J. Ratain, Dose-Finding and Pharmacokinetic Study to Optimize the Dosing of Irinotecan According to the UGT1A1 Genotype of Patients With Cancer Journal of Clinical Oncology. ,vol. 32, pp. 2328- 2334 ,(2014) , 10.1200/JCO.2014.55.2307
David L. Tabb, Lorenzo Vega-Montoto, Paul A. Rudnick, Asokan Mulayath Variyath, Amy-Joan L. Ham, David M. Bunk, Lisa E. Kilpatrick, Dean D. Billheimer, Ronald K. Blackman, Helene L. Cardasis, Steven A. Carr, Karl R. Clauser, Jacob D. Jaffe, Kevin A. Kowalski, Thomas A. Neubert, Fred E. Regnier, Birgit Schilling, Tony J. Tegeler, Mu Wang, Pei Wang, Jeffrey R. Whiteaker, Lisa J. Zimmerman, Susan J. Fisher, Bradford W. Gibson, Christopher R. Kinsinger, Mehdi Mesri, Henry Rodriguez, Stephen E. Stein, Paul Tempst, Amanda G. Paulovich, Daniel C. Liebler, Cliff Spiegelman, Repeatability and Reproducibility in Proteomic Identifications by Liquid Chromatography−Tandem Mass Spectrometry Journal of Proteome Research. ,vol. 9, pp. 761- 776 ,(2010) , 10.1021/PR9006365
Uwe Rix, Giulio Superti-Furga, Target profiling of small molecules by chemical proteomics Nature Chemical Biology. ,vol. 5, pp. 616- 624 ,(2009) , 10.1038/NCHEMBIO.216
Janyce F Rogers, Anne N Nafziger, Joseph S Bertino, Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450–metabolized drugs The American Journal of Medicine. ,vol. 113, pp. 746- 750 ,(2002) , 10.1016/S0002-9343(02)01363-3